NCT03206203View on ClinicalTrials.gov

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

August 29, 2017

Primary Completion Date

November 30, 2022

Study Completion Date

October 4, 2023

Conditions
Triple Negative Breast CancerStage IV Breast CancerHER2 NegativeInvasive Breast Cancer
Interventions
DRUG

Atezolizumab

Given by vein

DRUG

Carboplatin

Given by vein

OTHER

Laboratory Biomarker

Correlative study

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (6)

19104

University of Pennsylvania, Philadelphia

20057

Georgetown University Lombardi Comprehensive Cancer Center, Washington D.C.

21231

Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore

27599

University of North Carolina at Chapel Hill, Chapel Hill

37232

Vanderbilt-Ingram Cancer Center, Nashville

46202

Indiana University Health Melvin Bren Simon Cancer Center, Indianapolis

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Genentech, Inc.

INDUSTRY

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT03206203 - Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter